Licensing Deal Has Cara Therapeutics Stock Climbing The Nasdaq

The drug stock is heavily shorted

Managing Editor
May 23, 2018 at 10:20 AM
facebook X logo linkedin


Cara Therapeutics Inc (NASDAQ:CARA) is up 17.4% to trade at $13.62, one of the top gainers on the Nasdaq so far. Earlier this morning, the biotech company secured a licensing deal for its pruritus treatment for chronic kidney disease patients with European drug conglomerate Vifor Fresenius Medical Care Renal Pharma. The drug Korsuva will give Cara a $50 million upfront payment and $20 million stock investment, as well as up to $470 million in milestone payments, and will be licensed everywhere except the U.S, Japan, and South Korea. 

CARA stock is on track to post its best single-day gain since Aug. 4, and is now trading near the $14 level for the first time since mid-March -- attempting to fill a post-earnings bear gap. Prior to today's burst though, the shares had traded within a tight range between $11.50 and $13.00, with their 100- and 160-day moving averages keeping a tight lid on CARA. 

A short squeeze could give CARA even more room to run. Short interest is up 29% since the start of the year to 7.65 million shares sold short -- the most since mid-October. This represents a hefty 28% of the security's total available float, and nearly 18 days of pent-up buying power, at the stock's average trading volume. 

This skepticism is seen in the options pits, too, amid relatively light absolute volume. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the security's 10-day put/call volume ratio of 0.48 ranks in the elevated 91st percentile of its annual range. This shows that while calls are preferred on an absolute basis, puts have been bought to open at a much faster-than-usual clip during the past two weeks.

Today, options volume is running at a quick clip in early trading. At last check, 3,449 calls and 295 puts were on the tape -- more than four times the average daily volume of 871 contracts.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI